Search research articles
Contact Us
Filters
Showing results (11-20 of 77) with videos related to
Page
of 8
Sort By:
Social Science & Medicine (1982)
|
August 1, 1997
The impact of cost-effectiveness on public and private policies in health care: an international perspective. Introduction and overview
F A Sloan, H G Grabowski
Blood
|
July 1, 1997
Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase
E Ponce, J Moskovitz, G Grabowski
Clinical Pharmacology and Therapeutics
|
October 24, 2007
Should the patent system for new medicines be abolished?
J A DiMasi, H G Grabowski
Journal of Health Economics
|
November 4, 1994
Returns to R&D on new drug introductions in the 1980s
H G Grabowski, J M Vernon
Cancer Prevention Research (Philadelphia, Pa.)
|
January 14, 2009
Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention
Henry G Grabowski, Jeffrey L Moe
Talanta
|
April 1, 1995
The trifluoroacetic anhydride-sodium iodide system as a reagent for determination and microdetermination of nitroxide radicals
W Ciesielski, Z H Kudzin, G Grabowski
Health Affairs (Project Hope)
|
June 4, 2014
Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future
Henry G Grabowski, Rahul Guha, Maria Salgado
Aviation, Space, and Environmental Medicine
|
November 30, 2005
Ground crew injuries and fatalities in U.S. commercial aviation, 1983-2004
Jurek G Grabowski, Susan P Baker, Guohua Li
Health Affairs (Project Hope)
|
February 4, 2015
The roles of patents and research and development incentives in biopharmaceutical innovation
Henry G Grabowski, Joseph A DiMasi, Genia Long
Health Affairs (Project Hope)
|
March 9, 2006
Developing drugs for developing countries
David B Ridley, Henry G Grabowski, Jeffrey L Moe
Page
of 8
Search research articles
Search
Showing results (11-20 of 77) with videos related to
Sort By:
Page
of 8
Social Science & Medicine (1982)
|
August 1, 1997
The impact of cost-effectiveness on public and private policies in health care: an international perspective. Introduction and overview
F A Sloan, H G Grabowski
Blood
|
July 1, 1997
Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase
E Ponce, J Moskovitz, G Grabowski
Clinical Pharmacology and Therapeutics
|
October 24, 2007
Should the patent system for new medicines be abolished?
J A DiMasi, H G Grabowski
Journal of Health Economics
|
November 4, 1994
Returns to R&D on new drug introductions in the 1980s
H G Grabowski, J M Vernon
Cancer Prevention Research (Philadelphia, Pa.)
|
January 14, 2009
Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention
Henry G Grabowski, Jeffrey L Moe
Talanta
|
April 1, 1995
The trifluoroacetic anhydride-sodium iodide system as a reagent for determination and microdetermination of nitroxide radicals
W Ciesielski, Z H Kudzin, G Grabowski
Health Affairs (Project Hope)
|
June 4, 2014
Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future
Henry G Grabowski, Rahul Guha, Maria Salgado
Aviation, Space, and Environmental Medicine
|
November 30, 2005
Ground crew injuries and fatalities in U.S. commercial aviation, 1983-2004
Jurek G Grabowski, Susan P Baker, Guohua Li
Health Affairs (Project Hope)
|
February 4, 2015
The roles of patents and research and development incentives in biopharmaceutical innovation
Henry G Grabowski, Joseph A DiMasi, Genia Long
Health Affairs (Project Hope)
|
March 9, 2006
Developing drugs for developing countries
David B Ridley, Henry G Grabowski, Jeffrey L Moe
Page
of 8